Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: Roles of the nuclear factor of activated T cells and cyclooxygenase 2

Journal of Experimental Medicine

Volumn 193, Issue 5, 2001, Pages 607-620

  Hernández, Gabriela L ^a   Volpert, Olga V ^b   Íñiguez, Miguel A ^a   Lorenzo, Elisa ^a   Martínez Martínez, Sara ^a   Grau, Raquel ^a   Fresno, Manuel ^a   Redondo, Juan Miguel ^a  

^a CSIC   (Spain)

^b Robert H Lurie C Cancer Center ^*  (United States)

Author keywords

Angiogenesis; Cyclooxygenase; Cyclosporin A; NFAT; VEGF

Indexed keywords

CYCLOOXYGENASE 2; CYCLOSPORIN A; FIBROBLAST GROWTH FACTOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NUCLEAR FACTOR; PROSTAGLANDIN E2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MIGRATION INHIBITION; CELL MOVEMENT; CELLS, CULTURED; CORNEA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYCLOSPORINE; DINOPROSTONE; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; ISOENZYMES; LYMPHOKINES; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MUTAGENESIS, SITE-DIRECTED; NEOVASCULARIZATION, PHYSIOLOGIC; NFATC TRANSCRIPTION FACTORS; NITROBENZENES; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES; TRANSCRIPTION FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035809312     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.193.5.607     Document Type: Article

References (68)

1. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
2. Molecular and biological properties of vascular endothelial growth factor
3. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
4. VEGF is required for growth and survival in neonatal mice
5. The biology of vascular endothelial growth factor
6. Angiogenesis in cancer, vascular, rheumatoid and other diseases
7. Vascular endothelial growth factor is a potent tumor angiogenesis factor in human gliomas in vivo
8. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
9. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
10. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
11. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
12. Angiogenesis: How a tumor adapts to hypoxia
13. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
14. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells
15. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin
16. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: A role for tissue factor gene expression
17. Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT
18. Transcription factors of the NFAT family: Regulation and function
19. Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates transcription of several cytokine genes
20. NFATc3, a lymphoid-specific NFAT family member that is calcium-regulated and exhibits distinct DNA binding specificity
21. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp
22. Isolation of two new members of the NFAT gene family and functional characterization of the NFAT proteins
23. NFATx, a novel member of the nuclear factor of activated T cells family that is expressed predominantly in the thymus
24. NFAT components define a family of transcription factors targeted in T-cell activation
25. NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun
26. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity
27. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
28. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronic
29. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healin
30. Prostaglandin endoperoxide H synthases-1 and -2
31. Induction of cyclooxygenase-2 on activated T lymphocytes: Regulation of T cell activation by cyclooxygenase-2 inhibitors
32. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to date
33. Prostaglandin synthase 2
34. Cyclooxygenase gene expression is down-regulated by heparin-binding (acidic fibroblast) growth factor-1 in human endothelial cells
35. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways
36. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element
37. Phosphatidylinositol phospholipase C is activated allosterically by the aminoglycoside G418. 2-deoxy-2-fluoro-scyllo-inositol-1-O-dodecylphosphonate and its analogs inhibit glycosylphosphatidylinositol phospholipase C
38. v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element
39. Transcriptional roles of nuclear factor κB and nuclear factor-interleukin-6 in the tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells
40. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
41. Human cyclooxygenase-2 cDNA
42. Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical vein endothelial cells using specific immunometric enzyme immunoassays
43. Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells
44. Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone
45. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane
46. Transcriptional up-regulation of intracellular adhesion molecule-1 in human endothelial cells by the antioxidant pyrrolidine dithiocarbamate involves the activation of activating protein-1
47. Genomic sequencing
48. Dexamethasone induces lipocalin-type protaglandin D synthase gene expression in mouse neuronal cells
49. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes
50. Assays and purification of naturally occurring inhibitor of angiogenesis
51. Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT
52. Cyclosporine induces cancer progression by a cell-autonomous mechanism
53. Vascular endothelial growth factor upregulates constitutive cyclooxygenase 1 in primary bovine and human endothelial cells
54. Colorectal cancer and nonsteroidal anti-inflammatory drugs
55. Aspirin use and reduced risk of fatal colon cancer
56. The role of cyclooxygenases in inflammation, cancer and development
57. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
58. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
59. Role of the NFATc transcription factor in morphogenesis of cardiac valves and septum
60. The transcription factor NFATc is essential for cardiac valve formation
61. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A
62. Corneal neovascularization induced by xenografts or chemical cautery
63. Antiangiogenesis by cyclosporine
64. Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue
65. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis
66. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
67. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders